Company: SCLXW
Filing Date: 2025-05-07
Form Type: POS AM
Source: 0001193125-25-115054
Chunk: 203

Company: Scilex Holding Co
Filing Date: 2025-05-07
Form: POS AM
Chunk 203
---
 the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. Amendment to Common Stock Purchase Warrant On December 11, 2024, we entered into a warrant amendment (the “Warrant Amendment”) with one of the investors to exercise the outstanding amount of certain warrants that we issued to such investor in the February 2024 BDO on March 5, 2024. Pursuant to the Warrant Amendment, the investor agreed to exercise outstanding warrants to purchase an aggregate of 50,421 shares of Common Stock in cash at an amended exercise price of $20.65 per share. The gross proceeds to us from such exercise was approximately $1.0 million. Future Liquidity Needs We have based our anticipated operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources sooner than we expect. The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to:

| • |     | the costs and expenses associated with our ongoing commercialization efforts for ZTlido, GLOPERBA and ELYXYB; |

| • |     | the degree of success we experience in commercializing ZTlido, GLOPERBA and ELYXYB; |

| • |     | the revenue generated by sales of ZTlido, GLOPERBA, ELYXYB and other products that may be approved, if any; |

| • |     | the scope, progress, results and costs of conducting studies and clinical trials for our product candidates, SEMDEXA, SP-103 and SP-104; |

| • |     | the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates; |

| • |     | the costs of manufacturing ZTlido, GLOPERBA, ELYXYB and our product candidates; |

| • |     | the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current or future collaboration or license agreements; |

| • |     | our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; |

| • |     | the extent to which ZTlido, GLOPERBA, ELYXYB or any of our product candidates, if